Over the last three decades, gadolinium-based contrast agents (GBCAs) have been widely-used in magnetic resonance imaging (MRI). Over that time, GBCAs have been noted for their efficacy and safety in clinical use.
However, the radiology profession has recognized that advances in GBCAs could potentially be beneficial in reducing patient exposure to gadolinium, as well as reducing environmental impacts of gadolinium. One such advancement is the development of macrocyclic, high-relaxivity GBCAs, which are more stable than conventional, linear GBCAs, and can be used in lower recommended dosages.
In September of 2022, FDA marketing approval was granted for a novel macrocyclic, high-relaxivity GBCA. In this engaging breakfast presentation, leading MRI safety expert, Lawrence N. Tanenbaum, MD, FACR, will provide an overview of GBCAs and explore the clinical and environmental considerations of GBCAs.
Learning Objectives:
Describe general physicochemical properties of gadolinium-based contrast agents (GBCAs) including properties of the novel macrocyclic, high-relaxivity GBCA.
List and apply clinical considerations in choosing a GBCA for use in MRI.
Understand stability of a GBCA and how it can relate to nephrogenic systemic fibrosis (NSF) and gadolinium retention in the human body.
Identify the main environmental considerations relative to GBCA use and dosing.
